Clinical Trials and Clinical Research

Our dedicated Clinical Research Department offers innovative clinical research trials dedicated to fighting disease and improving the health and wellness of our patients.

Clinical trials include:

  • Psoriasis
  • Cellulite
  • Rosacea
  • Acne
  • Vitiligo
  • Double chin 
  • Hidradenitis Suppurativa
  • Atopic Dermatitis (Eczema)
  • Skin Cancer
  • Alopecia Areata
  • Actinic Keratosis
  • Gorlin Syndrome

Learn more about our Clinical Trials

Fill out the form below or call 609-443-0424

    What our patients say

    Why participate?

    Clinical trials include:

    • Access to the latest medical treatments
    • No cost to enroll
    • No insurance needed
    • You may be eligible to receive reimbursement for time & travel
    • Receive support from a dedicated team of dermatology professionals

    World-class Leadership

    Our Principal Investigators are award-winning dermatologists and are involved in every aspect of the patient visit

    Director of Clinical Research

    Hackensack, NJ

    East Windsor, NJ

    Coatesville, PA

    Exton, PA

    Featured Articles

    Cutera’s AviClearTM 12-Month Clinical Data Presented at the 42nd Annual Fall Clinical Dermatology Conference
    - Dr. David Goldberg

    Cutera, Inc. (Nasdaq: CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, today announced that the 12-month clinical data related to AviClear, the first and only FDA-cleared energy-based device for the treatment of mild, moderate, and severe acne, was presented at the Annual Fall Clinical Dermatology Conference, which took place October 20-23 in Las Vegas, Nevada.

    Current clinical studies show that after three 30-minute treatment sessions, 90% of patients had a visible improvement in their acne at 6 months.1 New 12-month clinical findings show this improvement increases to 92%,2 confirming the continual improvement of acne clearance and skin quality over time. Studies also demonstrate that three-fourths of patients showed a 2+ IGA score improvement and two-thirds of patients were assessed as clear or almost-clear 12 months after their final treatment session.3

    Read More

    Psoriasis Treatment Center of New Jersey Reports Positive Results for Tapinarof in Psoriasis Trial
    - Dr. Jerry Bagel

    The Psoriasis Treatment Center of New Jersey, a part of Schweiger Dermatology Group, has recently revealed encouraging findings from an open-label clinical trial involving tapinarof (VTAMA) cream 1%, in conjunction with injectable biologics for the treatment of adult plaque psoriasis. The trial aimed to achieve the National Psoriasis Foundation's (NPF) treat-to-target goal, reducing psoriasis to 1% body surface area (BSA) or less within 3 months.

    Conducted at a single center, the observational study enrolled 30 patients with at least 3% BSA who had been on stable biologic therapy for a minimum of 26 weeks. Eligible patients received tapinarof cream once daily for 12 weeks, in addition to their biologic regimen. Following the discontinuation of tapinarof cream at week 12, patients returned at week 16 for safety assessments and to evaluate maintenance response, with patient-reported outcomes collected from baseline through week 16.

    Read More

    About Schweiger Dermatology Group

    Schweiger Dermatology Group was founded to help make excellent dermatology care accessible throughout the Northeast. In 2010, Dr. Eric Schweiger started the practice with a single location in Midtown Manhattan. When he saw the need for high-quality dermatology care that did not require weeks or months of waiting to see a qualified provider, his vision of a multi-location practice was born.

    Back to Top